Solid Tumor Oncology Education Foundation Sponsors Free Local Seminars

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

SECAUCUS, NJ--To accommodate community-based physicians who may not be able to attend national professional meetings, the newly formed not-for-profit Solid Tumor Oncology Education Foundation, Inc. will sponsor a series of free local seminars and audioconferences, led by a faculty of expert physicians.

SECAUCUS, NJ--To accommodate community-based physicians who maynot be able to attend national professional meetings, the newlyformed not-for-profit Solid Tumor Oncology Education Foundation,Inc. will sponsor a series of free local seminars and audioconferences,led by a faculty of expert physicians.

The programs will focus on breast, colorectal, gastrointestinal,genitourinary, gynecologic, pancreatic, and lung cancers, andinclude such subjects as adjuvant and palliative therapy, currentand new protocol regimens, screening and diagnosis, and quality-of-lifeissues.

Beginning this month, the Foundation will offer a series of presentationsconducted at local, state, and regional oncology meetings by leadingoncolo-gists, as well as telephone audioconfer-ences, allowinghealth-care professionals to participate from their home or office.

The chairman of the Foundation is Paul A. Bunn, Jr., MD, Universityof Colorado Cancer Center. Board members are Laurence H. Baker,DO, University of Michigan Comprehensive Cancer Center; GabrielN. Hortobágyi, MD, University of Texas M.D. Anderson CancerCenter; John S. Macdonald, MD, Temple University Cancer Center;Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, and ElizabethJ. Shpall, MD, University of Colorado Health Sciences Center.

The formation of the Foundation was made possible by an unrestrictededucational grant from Lilly Oncology. Oncolo-gists can get moreinformation by calling 1-800-223-8978.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content